Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 6—June 2024
Research

Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark

Katrine Finderup Nielsen1Comments to Author , Lise Birk Nielsen1, Tine Dalby, Frederikke Kristensen Lomholt, Hans-Christian Slotved, Kurt Fuursted, Zitta Barrella Harboe, Charlotte Sværke Jørgensen, and Palle Valentiner-Branth
Author affiliations: Statens Serum Institut, Copenhagen, Denmark (K. Finderup Nielsen, L.B. Nielsen, T. Dalby, F.K. Lomholt, H.-C. Slotved, K. Fuursted, Z.B. Harboe, C.S. Jørgensen, P. Valentiner-Branth); Copenhagen University Hospital, North Zealand, Copenhagen (Z.B. Harboe); University of Copenhagen, Copenhagen (Z.B. Harboe)

Main Article

Figure

Flowchart of cohort development for follow-up study of effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease, Denmark.

Figure. Flowchart of cohort development for follow-up study of effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease, Denmark.

Main Article

1These authors contributed equally to this article.

Page created: April 10, 2024
Page updated: May 22, 2024
Page reviewed: May 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external